Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

4 Dec 2018 13:08

RNS Number : 4088J
Diurnal Group PLC
04 December 2018
 

4 December 2018

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the Market Abuse Regulations

 

On 4 December 2018, Diurnal issued a total of 1,217,259 par value options over ordinary shares of 5 pence in the Company under the Diurnal Group plc Long Term Incentive Plan (the "Plan"), of which the following were issued to persons discharging managerial responsibilities ("PDMR"):

 

PDMR

Total number of shares awarded

Type of awards

Martin Whitaker

255,105

Performance share award

Richard Bungay

204,083

Performance share award

Richard Ross

71,743

 

 

The performance share awards will ordinarily vest no earlier than the third anniversary of their grant subject to the grantee's continued service and to the extent to which the performance conditions set for the awards are satisfied. Such awards may potentially vest until the fifth anniversary of their grant date. The awards were granted under award agreements that incorporated the terms of the Plan. No consideration is due to be payable on vesting.

 

Details of the full notifications received by the Company are set out below:

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Martin Whitaker

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Grant of award of options under the Diurnal Group plc Long Term Incentive Plan over Ordinary shares of 5p each

 

 

Identification code

Ordinary shares: GB00BDB6Q760

 

 

b)

 

Nature of the transaction

 

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Performance share award over 255,105 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

No consideration is due to be payable on vesting.

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

Nil exercise price

255,105

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

Award over 255,105 ordinary shares.

 

 

- Price

Nil price payable for grant and upon exercise

 

 

e)

 

Date of the transaction

 

4 December 2018

f)

 

Place of the transaction

 

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Richard Bungay

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Grant of award of options under the Diurnal Group plc Long Term Incentive Plan over Ordinary shares of 5p each

 

 

Identification code

Ordinary shares: GB00BDB6Q760

 

 

b)

 

Nature of the transaction

 

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Performance share award over 204,083 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

No consideration is due to be payable on vesting.

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

Nil exercise price

204,083

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

Award over 204,083 ordinary shares.

 

 

- Price

Nil price payable for grant and upon exercise

 

 

e)

 

Date of the transaction

 

4 December 2018

f)

 

Place of the transaction

 

Outside a trading venue

 

 

Details of the person discharging managerial responsibilities / person closely associated

 

Name

 

 Richard Ross

Reason for the notification

 

Position/status

 

Chief Scientific Officer

Initial notification /Amendment

 

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

Name

 

Diurnal Group plc

LEI

 

213800I2HNUNZN1LDH29

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

Description of the financial instrument, type of instrument

Grant of award of options under the Diurnal Group plc Long Term Incentive Plan over Ordinary shares of 5p each

 

 

Identification code

Ordinary shares: GB00BDB6Q760

 

 

Nature of the transaction

 

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Performance share award over 71,743 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

No consideration is due to be payable on vesting.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

Nil exercise price

71,743

 

 

 

 

 

 

Aggregated information

 

 

 

- Aggregated volume

Award over 71,743 ordinary shares.

 

 

- Price

Nil price payable for grant and upon exercise

 

 

Date of the transaction

 

4 December 2018

Place of the transaction

 

Outside a trading venue

 

 

For further information, please visit www.diurnal.co.uk or contact:

 

 

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

 

Richard Bungay, Chief Financial Officer

 

 

 

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

 

Corporate Broking: James Stearns

 

 

 

Cantor Fitzgerald Europe (Joint Broker)

+44 (0)20 7894 7000

Corporate Finance: Phil Davies, Will Goode, Michael Boot

 

Healthcare Equity Sales: Andrew Keith

 

 

 

FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway

 

Victoria Foster Mitchell

 

 

 

Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFSUFELFASELE
Date   Source Headline
6th Mar 202011:22 amRNSProposed Placing
5th Mar 20204:41 pmRNSDirectorate Change
28th Feb 20207:30 amEQSHardman & Co Research: Diurnal (DNL): . and more to come (news flow)
25th Feb 20203:06 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 202011:00 amRNSPrice Monitoring Extension
17th Feb 20201:46 pmRNSHolding(s) in Company
13th Feb 20207:00 amRNSUS FDA Accepts NDA Application for Alkindi
11th Feb 20207:00 amRNSInterim Results
20th Jan 20207:00 amRNSBusiness and trading update
13th Jan 20207:00 amRNSHolding(s) in Company
13th Jan 20207:00 amRNSNotice of Interim Results
10th Jan 20203:45 pmRNSDirector Dealings and Issue of Equity
10th Jan 20203:44 pmRNSIssue of Long-Term Incentive Plan awards
16th Dec 201911:46 amRNSDirector Dealings
16th Dec 20197:00 amRNSChronocort MAA Submitted in Europe
2nd Dec 20192:28 pmRNSShare Option Exercise and Issue of Equity
2nd Dec 20197:01 amRNSHolding(s) in Company
2nd Dec 20197:00 amRNSAlkindi New Drug Application Submitted to US FDA
26th Nov 201910:42 amRNSDirector Dealings and Issue of Equity
26th Nov 20197:15 amEQSHardman & Co Research: Diurnal (DNL): Successful DITEST Phase I trial outcome
21st Nov 20191:08 pmRNSResults of Annual General Meeting
21st Nov 20197:00 amRNSAGM Statement
20th Nov 20197:00 amRNSSuccessful outcome of testosterone clinical study
8th Nov 20197:00 amRNSVesting of LTIP awards
5th Nov 20197:30 amEQSHardman & Co Research: Diurnal (DNL): Approaching a number of near-term milestones
21st Oct 20196:23 pmRNSIssue of Equity
21st Oct 20191:09 pmRNSDirector Dealings
8th Oct 201911:26 amRNSPosting of Annual Report and AGM Notice
24th Sep 20197:00 amRNSResults for the year ended 30 June 2019
7th Aug 201911:04 amRNSDirector Dealings
5th Aug 201912:27 pmRNSDirector/PDMR Shareholding
26th Jul 20194:32 pmRNSHolding(s) in Company
8th Jul 20192:07 pmRNSDirector Dealings and Issue of Equity
3rd Jul 20197:00 amRNSMarket Authorisation Application in Australia
26th Jun 20193:57 pmRNSHolding(s) in Company
24th Jun 20199:39 amRNSDirector Dealings
21st Jun 20193:40 pmRNSHolding(s) in Company
21st Jun 20193:35 pmRNSHolding(s) in Company - Replacement
21st Jun 201910:18 amRNSChange of Auditor
19th Jun 20194:08 pmRNSHolding(s) in Company
18th Jun 20195:30 pmRNSHolding(s) in Company
18th Jun 20192:03 pmRNSDirector Dealings
17th Jun 201912:05 pmRNSDirector Dealings
14th Jun 201912:39 pmRNSResult of General Meeting and Issue of Equity
14th Jun 20197:00 amRNSResult of Open Offer
28th May 20197:00 amRNSPlacing, Open Offer and Notice of General Meeting
9th May 20197:00 amRNSIntent to Submit for MAA tendered to the EMA
2nd May 20193:29 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.